Next-Generation Adeno-Associated Virus (AAV) Gene Therapy Delivery Global Market Report 2026

Description

Next-generation adeno-associated virus (AAV) gene therapy delivery involves advanced engineered AAV vector platforms designed to improve the accuracy, effectiveness, and safety of therapeutic gene delivery. These enhanced delivery systems utilize optimized AAV capsids to achieve better targeting of specific tissues, minimize immune system reactions, and provide sustained gene expression compared with earlier AAV-based approaches.

The primary types of next-generation adeno-associated virus (AAV) gene therapy delivery include recombinant adeno-associated virus, engineered capsid adeno-associated virus, and self-complementary adeno-associated virus. Recombinant adeno-associated virus refers to a genetically modified viral vector designed to safely deliver therapeutic genes into target cells for long-term gene expression with minimal pathogenicity. These vectors support in vivo delivery, ex vivo delivery, systemic delivery, and localized delivery methods and are administered through intravenous, intrathecal, intramuscular, and intravitreal routes. Their applications include neuromuscular disorders, ophthalmologic diseases, cardiovascular gene therapy, and rare metabolic disorders and they are utilized by hospitals, specialty clinics, research institutes, and biopharmaceutical companies.

Tariffs are influencing the next-generation adeno-associated virus (AAV) gene therapy delivery market by increasing the cost of imported bioprocessing equipment, specialized laboratory materials, and manufacturing components required for gene therapy production. The impact is more pronounced in regions dependent on global biotechnology supply chains, including North America, Europe, and Asia-Pacific, affecting biopharmaceutical companies, research institutes, and clinical therapy developers. Higher costs may increase research and development expenses and delay the expansion of manufacturing capacity for advanced AAV platforms. However, tariffs are also encouraging domestic biotechnology manufacturing, regional supply chain development, and investments in local gene therapy production capabilities.

The next-generation adeno-associated virus (aav) gene therapy delivery market research report is one of a series of new reports from The Business Research Company that provides next-generation adeno-associated virus (aav) gene therapy delivery market statistics, including next-generation adeno-associated virus (aav) gene therapy delivery industry global market size, regional shares, competitors with a next-generation adeno-associated virus (aav) gene therapy delivery market share, detailed next-generation adeno-associated virus (aav) gene therapy delivery market segments, market trends and opportunities, and any further data you may need to thrive in the next-generation adeno-associated virus (aav) gene therapy delivery industry. This next-generation adeno-associated virus (aav) gene therapy delivery market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The next-generation adeno-associated virus (AAV) gene therapy delivery market size has grown rapidly in recent years. It will grow from $4.96 billion in 2025 to $5.93 billion in 2026 at a compound annual growth rate (CAGR) of 19.5%. The growth during the historic period can be attributed to increasing gene therapy research activities, rising prevalence of rare genetic disorders, growing investment in biotechnology innovation, expanding clinical trials for AAV-based therapies, and increasing demand for targeted therapeutic approaches.

The next-generation adeno-associated virus (AAV) gene therapy delivery market size is expected to see rapid growth in the next few years. It will grow to $11.91 billion in 2030 at a compound annual growth rate (CAGR) of 19.1%. The growth in the forecast period can be attributed to increasing adoption of personalized gene therapies, rising development of advanced AAV vector engineering platforms, growing commercialization of gene therapy products, expanding research in precision medicine applications, and increasing demand for safer and more effective genetic treatments. Major trends in the forecast period include growing adoption of engineered AAV capsid technologies for targeted gene delivery, increasing development of immune response reduction strategies in AAV therapies, rising demand for durable and precise gene expression platforms, expanding applications of next-generation AAV vectors in rare disease treatments, and increasing focus on scalable manufacturing processes for advanced gene therapy vectors.

The increasing adoption of targeted gene therapies is expected to drive the growth of the next-generation adeno-associated virus gene therapy delivery market going forward. Targeted gene therapies refer to treatments that deliver genetic material to specific cells or tissues in the body to correct or modify disease-causing genes while reducing effects on non-target cells. The increasing adoption of targeted gene therapies is driven by advancements in gene delivery technologies that enhance precision, safety, and efficiency in delivering therapeutic genes directly to specific cells or tissues. The growing adoption of targeted gene therapies increases the demand for more accurate, efficient, and tissue-specific delivery systems, thereby accelerating the development and improvement of next-generation adeno-associated virus (AAV) gene therapy delivery platforms. For instance, in January 2024, according to the American Society of Gene & Cell Therapy, a US-based organization focused on gene and cell therapy, the number of gene therapies in Phase III increased by 10% in the fourth quarter of 2023 compared with the previous quarter, marking the first growth since the third quarter of 2022. Therefore, the increasing adoption of targeted gene therapies is contributing to the growth of the next-generation adeno-associated virus gene therapy delivery market.

Major companies operating in the next-generation adeno-associated virus gene therapy delivery market are focusing on developing innovative solutions, such as engineered capsids, to improve gene delivery efficiency, reduce dosage requirements, and enhance overall safety and therapeutic outcomes. Engineered capsids are genetically modified protein shells of adeno-associated viruses (AAVs) developed to enhance gene delivery by improving tissue targeting, increasing transduction efficiency, and minimizing immune system recognition. For instance, in May 2026, Affinia Therapeutics, a US-based biotechnology company, presented new preclinical and translational data at a leading gene and cell therapy conference, showcasing advancements in its AAV gene therapy platform. The update highlighted progress in capsid engineering, scalable manufacturing processes, and clinical development strategies aimed at improving targeted gene delivery performance. Its lead candidate, AFTX-201, was highlighted for its potential in treating BAG3-associated dilated cardiomyopathy through improved cardiac-specific gene expression enabled by its proprietary AAV vector technology.

In January 2024, Novartis AG, a Switzerland-based multinational pharmaceutical company focused on innovative medicines and advanced gene therapies, expanded its collaboration with Voyager Therapeutics through a deal valued at up to $1.2 billion to develop next-generation gene therapies for neurological diseases. Under this collaboration, Novartis aims to utilize Voyager's proprietary TRACER adeno-associated virus (AAV) capsid platform to enhance central nervous system (CNS) targeting, improve blood-brain barrier penetration, and enable more effective gene delivery for conditions such as Huntington's disease and spinal muscular atrophy. Voyager Therapeutics Inc. is a US-based biotechnology company specializing in engineered AAV capsids and gene therapy delivery technologies focused on neurological disorders.

Major companies operating in the next-generation adeno-associated virus (aav) gene therapy delivery market are Pfizer Inc., Novartis AG, Bayer AG, Astellas Pharma Inc., Sarepta Therapeutics Inc., Adverum Biotechnologies Inc., uniQure N.V., REGENXBIO Inc., Rocket Pharmaceuticals Inc., MeiraGTx Holdings plc, 4D Molecular Therapeutics, Voyager Therapeutics Inc., Taysha Gene Therapies Inc., Passage Bio Inc., Solid Biosciences Inc., Affinia Therapeutics Inc., Encoded Therapeutics Inc., Capsida Biotherapeutics Inc, AAVantgarde Bio S.r.l., VectorY Therapeutics B.V., Ring Therapeutics, Dyno Therapeutics Inc., Genethon, Sangamo Therapeutics Inc.

North America was the dominating region in the next-generation adeno-associated virus (AAV) gene therapy delivery market in 2025. Asia-Pacific is expected to be the rapidly growing region in the forecast period. The regions covered in the next-generation adeno-associated virus (AAV) gene therapy delivery market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the next-generation adeno-associated virus (AAV) gene therapy delivery market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The next-generation adeno-associated virus (AAV) gene therapy delivery market consists of revenues earned by entities by providing services such as viral vector engineering services, gene delivery optimization services, capsid modification services, targeted gene transfer services, preclinical and clinical development services. The market value includes the value of related goods sold by the service provider or included within the service offering. The next-generation adeno-associated virus (AAV) gene therapy delivery market also includes sales of gene delivery platforms, tissue-targeted gene therapy vectors, viral vector manufacturing systems, and adeno-associated virus-based therapeutic delivery products. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Next-Generation Adeno-Associated Virus (AAV) Gene Therapy Delivery Market Global Report 2026 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses next-generation adeno-associated virus (aav) gene therapy delivery market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
Create regional and country strategies on the basis of local data and analysis.
Identify growth segments for investment.
Outperform competitors using forecast data and the drivers and trends shaping the market.
Understand customers based on end user analysis.
Benchmark performance against key competitors based on market share, innovation, and brand strength.
Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for next-generation adeno-associated virus (aav) gene therapy delivery ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The next-generation adeno-associated virus (aav) gene therapy delivery market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
Market segmentations break down the market into sub markets.
The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.

Scope

Markets Covered:1) By Type: Recombinant Adeno Associated Virus; Engineered Capsid Adeno Associated Virus; Self Complementary Adeno Associated Virus
2) By Delivery Method: In Vivo Delivery; Ex Vivo Delivery; Systemic Delivery; Localized Delivery
3) By Route Of Administration: Intravenous; Intrathecal; Intramuscular; Intravitreal
4) By Application: Neuromuscular Disorders; Ophthalmologic Diseases; Cardiovascular Gene Therapy; Rare Metabolic Disorders
5) By End User: Hospitals; Specialty Clinics; Research Institutes; Biopharmaceutical Companies
Subsegments:
1) By Recombinant Adeno Associated Virus: Serotype Diversity Variants; Tissue Tropism Optimized Vectors; Promoter Engineered Constructs; Genome Modified Vector Designs
2) By Engineered Capsid Adeno Associated Virus: Directed Evolution Capsids; Rationally Designed Capsids; Chimeric Capsid Variants; Peptide Insert Capsid Systems
3) By Self Complementary Adeno Associated Virus: Double Stranded Genome Vectors; Rapid Expression Vectors; Low Dose Therapeutic Vectors; Tissue Targeted Expression Vectors
Companies Mentioned: Pfizer Inc.; Novartis AG; Bayer AG; Astellas Pharma Inc.; Sarepta Therapeutics Inc.; Adverum Biotechnologies Inc.; uniQure N.V.; REGENXBIO Inc.; Rocket Pharmaceuticals Inc.; MeiraGTx Holdings plc; 4D Molecular Therapeutics; Voyager Therapeutics Inc.; Taysha Gene Therapies Inc.; Passage Bio Inc.; Solid Biosciences Inc.; Affinia Therapeutics Inc.; Encoded Therapeutics Inc.; Capsida Biotherapeutics Inc; AAVantgarde Bio S.r.l.; VectorY Therapeutics B.V.; Ring Therapeutics; Dyno Therapeutics Inc.; Genethon; Sangamo Therapeutics Inc.
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Taiwan; Russia; South Korea; UK; USA; Canada; Italy; Spain
Regions: Asia-Pacific; South East Asia; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: Word, PDF or Interactive Report
+ Excel Dashboard
Added Benefits
Bi-Annual Data Update
Customisation
Expert Consultant Support

Added Benefits available all on all list-price licence purchases, to be claimed at time of purchase. Customisations within report scope and limited to 20% of content and consultant support time limited to 8 hours.

Product Code: PH5MNGAA01_G26Q3

1. Executive Summary

1.1. Key Market Insights (2020-2035)
1.2. Visual Dashboard: Market Size, Growth Rate, Hotspots
1.3. Major Factors Driving the Market
1.4. Top Three Trends Shaping the Market

2. Next-Generation Adeno-Associated Virus (AAV) Gene Therapy Delivery Market Characteristics

2.1. Market Definition & Scope
2.2. Market Segmentations
2.3. Overview of Key Products and Services
2.4. Global Next-Generation Adeno-Associated Virus (AAV) Gene Therapy Delivery Market Attractiveness Scoring And Analysis
- 2.4.1. Overview of Market Attractiveness Framework
- 2.4.2. Quantitative Scoring Methodology
- 2.4.3. Factor-Wise Evaluation
Growth Potential Analysis, Competitive Dynamics Assessment, Strategic Fit Assessment And Risk Profile Evaluation

2.4.4. Market Attractiveness Scoring and Interpretation
2.4.5. Strategic Implications and Recommendations

3. Next-Generation Adeno-Associated Virus (AAV) Gene Therapy Delivery Market Supply Chain Analysis

3.1. Overview of the Supply Chain and Ecosystem
3.2. List Of Key Raw Materials, Resources & Suppliers
3.3. List Of Major Distributors and Channel Partners
3.4. List Of Major End Users

4. Global Next-Generation Adeno-Associated Virus (AAV) Gene Therapy Delivery Market Trends And Strategies

4.1. Key Technologies & Future Trends
- 4.1.1 Biotechnology, Genomics & Precision Medicine
- 4.1.2 Artificial Intelligence & Autonomous Intelligence
- 4.1.3 Digitalization, Cloud, Big Data & Cybersecurity
- 4.1.4 Industry 4.0 & Intelligent Manufacturing
- 4.1.5 Sustainability, Climate Tech & Circular Economy
4.2. Major Trends
- 4.2.1 Increasing adoption of engineered AAV capsid technologies for targeted gene delivery
- 4.2.2 Growing development of immune response reduction strategies in AAV therapies
- 4.2.3 Rising demand for durable and precise gene expression platforms
- 4.2.4 Expanding applications of next-generation AAV vectors in rare disease treatments
- 4.2.5 Increasing focus on scalable manufacturing processes for advanced gene therapy vectors

5. Next-Generation Adeno-Associated Virus (AAV) Gene Therapy Delivery Market Analysis Of End Use Industries

5.1 Biopharmaceutical Companies
5.2 Research Institutes
5.3 Hospitals
5.4 Specialty Clinics
5.5 Other End Users

6. Next-Generation Adeno-Associated Virus (AAV) Gene Therapy Delivery Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, Supply Chain Impact from Tariff War & Trade Protectionism, And Covid And Recovery On The Market

7. Global Next-Generation Adeno-Associated Virus (AAV) Gene Therapy Delivery Strategic Analysis Framework, Current Market Size, Market Comparisons And Growth Rate Analysis

7.1. Global Next-Generation Adeno-Associated Virus (AAV) Gene Therapy Delivery PESTEL Analysis (Political, Economical, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
7.2. Global Next-Generation Adeno-Associated Virus (AAV) Gene Therapy Delivery Market Size, Comparisons And Growth Rate Analysis
7.3. Global Next-Generation Adeno-Associated Virus (AAV) Gene Therapy Delivery Historic Market Size and Growth, 2020 - 2025, Value ($ Billion)
7.4. Global Next-Generation Adeno-Associated Virus (AAV) Gene Therapy Delivery Forecast Market Size and Growth, 2025 - 2030, 2035F, Value ($ Billion)

8. Global Next-Generation Adeno-Associated Virus (AAV) Gene Therapy Delivery Total Addressable Market (TAM) Analysis for the Market

8.1. Definition and Scope of Total Addressable Market (TAM)
8.2. Methodology and Assumptions
8.3. Global Total Addressable Market (TAM) Estimation
8.4. TAM vs. Current Market Size Analysis
8.5. Strategic Insights and Growth Opportunities from TAM Analysis

9. Next-Generation Adeno-Associated Virus (AAV) Gene Therapy Delivery Market Segmentation

9.1. Global Next-Generation Adeno-Associated Virus (AAV) Gene Therapy Delivery Market, Segmentation By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
Recombinant Adeno Associated Virus, Engineered Capsid Adeno Associated Virus, Self Complementary Adeno Associated Virus
9.2. Global Next-Generation Adeno-Associated Virus (AAV) Gene Therapy Delivery Market, Segmentation By Delivery Method, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
In Vivo Delivery, Ex Vivo Delivery, Systemic Delivery, Localized Delivery
9.3. Global Next-Generation Adeno-Associated Virus (AAV) Gene Therapy Delivery Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
Intravenous, Intrathecal, Intramuscular, Intravitreal
9.4. Global Next-Generation Adeno-Associated Virus (AAV) Gene Therapy Delivery Market, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
Neuromuscular Disorders, Ophthalmologic Diseases, Cardiovascular Gene Therapy, Rare Metabolic Disorders
9.5. Global Next-Generation Adeno-Associated Virus (AAV) Gene Therapy Delivery Market, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
Hospitals, Specialty Clinics, Research Institutes, Biopharmaceutical Companies
9.6. Global Next-Generation Adeno-Associated Virus (AAV) Gene Therapy Delivery Market, Sub-Segmentation Of Recombinant Adeno Associated Virus, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
Serotype Diversity Variants, Tissue Tropism Optimized Vectors, Promoter Engineered Constructs, Genome Modified Vector Designs
9.7. Global Next-Generation Adeno-Associated Virus (AAV) Gene Therapy Delivery Market, Sub-Segmentation Of Engineered Capsid Adeno Associated Virus, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
Directed Evolution Capsids, Rationally Designed Capsids, Chimeric Capsid Variants, Peptide Insert Capsid Systems
9.8. Global Next-Generation Adeno-Associated Virus (AAV) Gene Therapy Delivery Market, Sub-Segmentation Of Self Complementary Adeno Associated Virus, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
Double Stranded Genome Vectors, Rapid Expression Vectors, Low Dose Therapeutic Vectors, Tissue Targeted Expression Vectors

10. Next-Generation Adeno-Associated Virus (AAV) Gene Therapy Delivery Market Regional And Country Analysis

10.1. Global Next-Generation Adeno-Associated Virus (AAV) Gene Therapy Delivery Market, Split By Region, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
10.2. Global Next-Generation Adeno-Associated Virus (AAV) Gene Therapy Delivery Market, Split By Country, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

11. Asia-Pacific Next-Generation Adeno-Associated Virus (AAV) Gene Therapy Delivery Market

11.1. Asia-Pacific Next-Generation Adeno-Associated Virus (AAV) Gene Therapy Delivery Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
11.2. Asia-Pacific Next-Generation Adeno-Associated Virus (AAV) Gene Therapy Delivery Market, Segmentation By Type, Segmentation By Delivery Method, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

12. China Next-Generation Adeno-Associated Virus (AAV) Gene Therapy Delivery Market

12.1. China Next-Generation Adeno-Associated Virus (AAV) Gene Therapy Delivery Market Overview
Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
12.2. China Next-Generation Adeno-Associated Virus (AAV) Gene Therapy Delivery Market, Segmentation By Type, Segmentation By Delivery Method, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

13. India Next-Generation Adeno-Associated Virus (AAV) Gene Therapy Delivery Market

13.1. India Next-Generation Adeno-Associated Virus (AAV) Gene Therapy Delivery Market, Segmentation By Type, Segmentation By Delivery Method, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

14. Japan Next-Generation Adeno-Associated Virus (AAV) Gene Therapy Delivery Market

14.1. Japan Next-Generation Adeno-Associated Virus (AAV) Gene Therapy Delivery Market Overview
Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
14.2. Japan Next-Generation Adeno-Associated Virus (AAV) Gene Therapy Delivery Market, Segmentation By Type, Segmentation By Delivery Method, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

15. Australia Next-Generation Adeno-Associated Virus (AAV) Gene Therapy Delivery Market

15.1. Australia Next-Generation Adeno-Associated Virus (AAV) Gene Therapy Delivery Market, Segmentation By Type, Segmentation By Delivery Method, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

16. Indonesia Next-Generation Adeno-Associated Virus (AAV) Gene Therapy Delivery Market

16.1. Indonesia Next-Generation Adeno-Associated Virus (AAV) Gene Therapy Delivery Market, Segmentation By Type, Segmentation By Delivery Method, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

17. South Korea Next-Generation Adeno-Associated Virus (AAV) Gene Therapy Delivery Market

17.1. South Korea Next-Generation Adeno-Associated Virus (AAV) Gene Therapy Delivery Market Overview
Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
17.2. South Korea Next-Generation Adeno-Associated Virus (AAV) Gene Therapy Delivery Market, Segmentation By Type, Segmentation By Delivery Method, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

18. Taiwan Next-Generation Adeno-Associated Virus (AAV) Gene Therapy Delivery Market

18.1. Taiwan Next-Generation Adeno-Associated Virus (AAV) Gene Therapy Delivery Market Overview
Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
18.2. Taiwan Next-Generation Adeno-Associated Virus (AAV) Gene Therapy Delivery Market, Segmentation By Type, Segmentation By Delivery Method, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

19. South East Asia Next-Generation Adeno-Associated Virus (AAV) Gene Therapy Delivery Market

19.1. South East Asia Next-Generation Adeno-Associated Virus (AAV) Gene Therapy Delivery Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
19.2. South East Asia Next-Generation Adeno-Associated Virus (AAV) Gene Therapy Delivery Market, Segmentation By Type, Segmentation By Delivery Method, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

20. Western Europe Next-Generation Adeno-Associated Virus (AAV) Gene Therapy Delivery Market

20.1. Western Europe Next-Generation Adeno-Associated Virus (AAV) Gene Therapy Delivery Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
20.2. Western Europe Next-Generation Adeno-Associated Virus (AAV) Gene Therapy Delivery Market, Segmentation By Type, Segmentation By Delivery Method, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

21. UK Next-Generation Adeno-Associated Virus (AAV) Gene Therapy Delivery Market

21.1. UK Next-Generation Adeno-Associated Virus (AAV) Gene Therapy Delivery Market, Segmentation By Type, Segmentation By Delivery Method, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

22. Germany Next-Generation Adeno-Associated Virus (AAV) Gene Therapy Delivery Market

22.1. Germany Next-Generation Adeno-Associated Virus (AAV) Gene Therapy Delivery Market, Segmentation By Type, Segmentation By Delivery Method, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

23. France Next-Generation Adeno-Associated Virus (AAV) Gene Therapy Delivery Market

23.1. France Next-Generation Adeno-Associated Virus (AAV) Gene Therapy Delivery Market, Segmentation By Type, Segmentation By Delivery Method, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

24. Italy Next-Generation Adeno-Associated Virus (AAV) Gene Therapy Delivery Market

24.1. Italy Next-Generation Adeno-Associated Virus (AAV) Gene Therapy Delivery Market, Segmentation By Type, Segmentation By Delivery Method, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

25. Spain Next-Generation Adeno-Associated Virus (AAV) Gene Therapy Delivery Market

25.1. Spain Next-Generation Adeno-Associated Virus (AAV) Gene Therapy Delivery Market, Segmentation By Type, Segmentation By Delivery Method, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

26. Eastern Europe Next-Generation Adeno-Associated Virus (AAV) Gene Therapy Delivery Market

26.1. Eastern Europe Next-Generation Adeno-Associated Virus (AAV) Gene Therapy Delivery Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
26.2. Eastern Europe Next-Generation Adeno-Associated Virus (AAV) Gene Therapy Delivery Market, Segmentation By Type, Segmentation By Delivery Method, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

27. Russia Next-Generation Adeno-Associated Virus (AAV) Gene Therapy Delivery Market

27.1. Russia Next-Generation Adeno-Associated Virus (AAV) Gene Therapy Delivery Market, Segmentation By Type, Segmentation By Delivery Method, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

28. North America Next-Generation Adeno-Associated Virus (AAV) Gene Therapy Delivery Market

28.1. North America Next-Generation Adeno-Associated Virus (AAV) Gene Therapy Delivery Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
28.2. North America Next-Generation Adeno-Associated Virus (AAV) Gene Therapy Delivery Market, Segmentation By Type, Segmentation By Delivery Method, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

29. USA Next-Generation Adeno-Associated Virus (AAV) Gene Therapy Delivery Market

29.1. USA Next-Generation Adeno-Associated Virus (AAV) Gene Therapy Delivery Market Overview
Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
29.2. USA Next-Generation Adeno-Associated Virus (AAV) Gene Therapy Delivery Market, Segmentation By Type, Segmentation By Delivery Method, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

30. Canada Next-Generation Adeno-Associated Virus (AAV) Gene Therapy Delivery Market

30.1. Canada Next-Generation Adeno-Associated Virus (AAV) Gene Therapy Delivery Market Overview
Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
30.2. Canada Next-Generation Adeno-Associated Virus (AAV) Gene Therapy Delivery Market, Segmentation By Type, Segmentation By Delivery Method, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

31. South America Next-Generation Adeno-Associated Virus (AAV) Gene Therapy Delivery Market

31.1. South America Next-Generation Adeno-Associated Virus (AAV) Gene Therapy Delivery Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
31.2. South America Next-Generation Adeno-Associated Virus (AAV) Gene Therapy Delivery Market, Segmentation By Type, Segmentation By Delivery Method, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

32. Brazil Next-Generation Adeno-Associated Virus (AAV) Gene Therapy Delivery Market

32.1. Brazil Next-Generation Adeno-Associated Virus (AAV) Gene Therapy Delivery Market, Segmentation By Type, Segmentation By Delivery Method, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

33. Middle East Next-Generation Adeno-Associated Virus (AAV) Gene Therapy Delivery Market

33.1. Middle East Next-Generation Adeno-Associated Virus (AAV) Gene Therapy Delivery Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
33.2. Middle East Next-Generation Adeno-Associated Virus (AAV) Gene Therapy Delivery Market, Segmentation By Type, Segmentation By Delivery Method, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

34. Africa Next-Generation Adeno-Associated Virus (AAV) Gene Therapy Delivery Market

34.1. Africa Next-Generation Adeno-Associated Virus (AAV) Gene Therapy Delivery Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
34.2. Africa Next-Generation Adeno-Associated Virus (AAV) Gene Therapy Delivery Market, Segmentation By Type, Segmentation By Delivery Method, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

35. Next-Generation Adeno-Associated Virus (AAV) Gene Therapy Delivery Market Regulatory and Investment Landscape

36. Next-Generation Adeno-Associated Virus (AAV) Gene Therapy Delivery Market Competitive Landscape And Company Profiles

36.1. Next-Generation Adeno-Associated Virus (AAV) Gene Therapy Delivery Market Competitive Landscape And Market Share 2024
- 36.1.1. Top 10 Companies (Ranked by revenue/share)
36.2. Next-Generation Adeno-Associated Virus (AAV) Gene Therapy Delivery Market - Company Scoring Matrix
- 36.2.1. Market Revenues
- 36.2.2. Product Innovation Score
- 36.2.3. Brand Recognition
36.3. Next-Generation Adeno-Associated Virus (AAV) Gene Therapy Delivery Market Company Profiles
- 36.3.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
- 36.3.2. Novartis AG Overview, Products and Services, Strategy and Financial Analysis
- 36.3.3. Bayer AG Overview, Products and Services, Strategy and Financial Analysis
- 36.3.4. Astellas Pharma Inc. Overview, Products and Services, Strategy and Financial Analysis
- 36.3.5. Sarepta Therapeutics Inc. Overview, Products and Services, Strategy and Financial Analysis

37. Next-Generation Adeno-Associated Virus (AAV) Gene Therapy Delivery Market Other Major And Innovative Companies

Adverum Biotechnologies Inc., uniQure N.V., REGENXBIO Inc., Rocket Pharmaceuticals Inc., MeiraGTx Holdings plc, 4D Molecular Therapeutics, Voyager Therapeutics Inc., Taysha Gene Therapies Inc., Passage Bio Inc., Solid Biosciences Inc., Affinia Therapeutics Inc., Encoded Therapeutics Inc., Capsida Biotherapeutics Inc, AAVantgarde Bio S.r.l., VectorY Therapeutics B.V.

38. Global Next-Generation Adeno-Associated Virus (AAV) Gene Therapy Delivery Market Competitive Benchmarking And Dashboard

39. Upcoming Startups in the Market

40. Key Mergers And Acquisitions In The Next-Generation Adeno-Associated Virus (AAV) Gene Therapy Delivery Market

41. Next-Generation Adeno-Associated Virus (AAV) Gene Therapy Delivery Market High Potential Countries, Segments and Strategies

41.1 Next-Generation Adeno-Associated Virus (AAV) Gene Therapy Delivery Market In 2030 - Countries Offering Most New Opportunities
41.2 Next-Generation Adeno-Associated Virus (AAV) Gene Therapy Delivery Market In 2030 - Segments Offering Most New Opportunities
41.3 Next-Generation Adeno-Associated Virus (AAV) Gene Therapy Delivery Market In 2030 - Growth Strategies
- 41.3.1 Market Trend Based Strategies
- 41.3.2 Competitor Strategies

42. Appendix

42.1. Abbreviations
42.2. Currencies
42.3. Historic And Forecast Inflation Rates
42.4. Research Inquiries
42.5. The Business Research Company
42.6. Copyright And Disclaimer